Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20407367 | 0.88 | — | — | |
| SCHEMBL8045069 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PIK3CDHSD11B1 | |
| SCHEMBL20343385 | 0.79 | MAPT (0.48) | KDM4EALDH1A1TDP1GAAPIK3CD | |
| SCHEMBL22954716 | 0.78 | ALDH1A1 (0.39) | KDM4EALDH1A1TDP1SMN1; SMN2MAPT | |
| SCHEMBL12850091 | 0.74 | KDM4E (0.37) | KDM4EALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL12229557 | 0.74 | CHRM5 (0.41) | ALDH1A1TDP1SMN1; SMN2MAPT | |
| SCHEMBL16075561 | 0.74 | ALDH1A1 (0.42) | ALDH1A1TDP1GAASMN1; SMN2KMT2A | |
| SCHEMBL27781490 | 0.74 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2HSD11B1TP53 | |
| SCHEMBL12605195 | 0.72 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2HSD11B1TP53 | |
| SCHEMBL3729620 | 0.72 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2HSD11B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | KDM4E 4774/4885ALDH1A1 4848/4885TDP1 3429/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | KDM4E 4774/4885ALDH1A1 4848/4885TDP1 3429/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | KDM4E 4774/4885ALDH1A1 4848/4885TDP1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.